A Double-Blind, Multi-Center, Placebo-Controlled Trial of SABER-Bupivacaine for Post-Operative Pain Control and Opioid Sparing/Opioid-Related Adverse Event Reduction Following Arthroscopic Shoulder Surgery.

Trial Profile

A Double-Blind, Multi-Center, Placebo-Controlled Trial of SABER-Bupivacaine for Post-Operative Pain Control and Opioid Sparing/Opioid-Related Adverse Event Reduction Following Arthroscopic Shoulder Surgery.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2015

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 08 Jun 2010 Status changed from completed to not yet recruiting as reported by ClinicalTrials.gov (NCT01139866).
    • 12 Feb 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 05 Feb 2010 Company added in association field as reported by ClinicalTrials.gov. (Parent trial: NCT00818363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top